Insmed (INSM) Expected to Announce Earnings on Thursday

Key Points

• Insmed is set to announce its Q3 2025 earnings on October 30, 2025, with analysts predicting a loss of $1.35 per share and revenues of $114.33 million.
• In its previous quarter, Insmed reported a loss of ($1.70) per share, missing estimates, though revenue increased by 18.9% year-over-year.
• Insider trading activity has been notable, with recent sales from executives leading to a 30.66% decrease in one insider's ownership stake.

Insmed (NASDAQ:INSM - Get Free Report) is expected to be issuing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($1.35) per share and revenue of $114.3320 million for the quarter. Insmed has set its FY 2025 guidance at EPS.Individuals may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm's revenue was up 18.9% on a year-over-year basis. During the same period last year, the company earned ($1.94) earnings per share. On average, analysts expect Insmed to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Insmed Price Performance

Shares of INSM opened at $160.40 on Thursday. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $168.21. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company has a market capitalization of $33.91 billion, a P/E ratio of -28.09 and a beta of 1.03. The business's 50-day moving average is $146.10 and its two-hundred day moving average is $106.75.

Insider Buying and Selling at Insmed

In related news, insider Michael Alexander Smith sold 24,272 shares of Insmed stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the transaction, the insider owned 54,902 shares in the company, valued at $7,899,848.78. The trade was a 30.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of the business's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the transaction, the director owned 262,675 shares of the company's stock, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 152,657 shares of company stock valued at $21,442,198. Insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of INSM. EverSource Wealth Advisors LLC grew its stake in Insmed by 65.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company's stock worth $67,000 after buying an additional 263 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Insmed by 80.8% during the 2nd quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company's stock valued at $4,770,000 after acquiring an additional 21,176 shares during the period. Baird Financial Group Inc. acquired a new position in Insmed during the second quarter worth about $2,589,000. Amundi increased its position in Insmed by 21,194.4% during the second quarter. Amundi now owns 11,499 shares of the biopharmaceutical company's stock worth $1,130,000 after buying an additional 11,445 shares in the last quarter. Finally, Natixis purchased a new stake in shares of Insmed during the second quarter worth about $1,072,000.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Mizuho upped their target price on Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. TD Cowen lifted their price objective on Insmed from $154.00 to $193.00 and gave the stock a "buy" rating in a report on Thursday, October 2nd. Royal Bank Of Canada boosted their price target on Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Guggenheim increased their target price on shares of Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a research report on Monday, September 8th. Finally, William Blair initiated coverage on Insmed in a report on Wednesday, August 20th. They issued an "outperform" rating for the company. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $152.88.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.